- Cosmo Pharmaceuticals (OTC: CMOPF) received an MSCI ESG rating upgrade to "A" from "BBB".
- The company's LSEG ESG score doubled to 62.98, ranking #42 globally among peers.
- Cosmo joined the UN Global Compact and committed to the Science Based Targets initiative for emissions reduction.
Cosmo Pharmaceuticals (OTC: CMOPF), a leader in AI-powered healthcare and specialty pharma, has significantly advanced its Environmental, Social, and Governance (ESG) initiatives. The company has achieved an upgrade in its MSCI ESG rating from "BBB" to "A", reflecting substantial progress in areas such as carbon emissions management, workforce engagement, and governance at the board level, placing it ahead of many mid-cap peers globally.
Additionally, Cosmo has doubled its LSEG ESG score to 62.98, now ranking 42nd globally within its peer group. This improvement signifies increased investor confidence and substantiates the company's commitment to sustainability, making it a more attractive option for ESG-focused investment funds, particularly those complying with SFDR Articles 8 and 9.
In alignment with its Vision 2030 strategy, Cosmo has become a signatory to the United Nations Global Compact, the largest corporate sustainability initiative worldwide, and has committed to the Science Based Targets initiative (SBTi). This move underscores the company's dedication to setting science-based emissions reduction targets consistent with the Paris Agreement, further solidifying its reputation as a leader in sustainable healthcare innovation.
CEO Giovanni Di Napoli emphasized that these milestones represent Cosmo's ambition to integrate scientific innovation, operational excellence, and environmental stewardship. Niall Donnelly, EVP Corporate Governance and Chief Sustainability Officer, added that the enhancements are a result of years of internal work, demonstrating Cosmo’s firm commitment to ESG principles that are both measurable and investor-relevant.
